Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

AAA Biotech Launches Validated Antibodies & Research Reagents Browse AAA Biotech's new range of validated antibodies, ELISA kits, and cultu ...

This research produced a highly-specific and sensitive anti-T-2 toxin monoclonal antibody (mAb), and developed a rapid and sensitive competitive indirect enzyme-linked immunosorbent assay (ELISA) ...

The global Custom Antibody Market is valued at USD 553.05 Million in 2024 and is projected to reach a value of USD 1237.1 ...

To contain the outbreak, authorities have set up a 24-hour control room, formed a 25-member response team, and established a ...

A group from Nagoya University in Japan has developed a simple, accurate, and sensitive method for measuring polysialic acid, ...

In a bold move that could reshape the future of biomedical research, Boster Bio is launching a Free Antibody Validation ...

ABBV-706 is an ADC targeting SEZ6 developed by AbbVie. It is linked to a topoisomerase 1 inhibitor (TOP1i) via a ...

During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...

PCMC has launched probe against hospital in Wakad for allegedly charging more than ₹600 fixed by state government for dengue tests, said officials ...

Antibody-drug conjugates (ADCs) represent a mechanistically defined class of targeted therapeutics that combine monoclonal antibodies with cytotoxic payloads to achieve selective delivery to ...